Ipsen announces the completion of the acquisition of Albireo Pharma, a leading innovator in the field of bile acid modulators for the treatment of rare liver diseases, an acquisition announced in January.

The acquisition complements Ipsen's portfolio with promising treatments for rare cholestatic liver diseases, innovative products with real potential in development, as well as scientific and commercial capabilities.

As part of the transaction, Ipsen is acquiring all the issued and outstanding shares of Albireo at a price of $42 per share in cash, plus a non-transferable guaranteed value certificate (GVC) of $10 per share.

Copyright (c) 2023 CercleFinance.com. All rights reserved.